The study by Ge et al. suggests that reversing the P-gp overexpression and potential collateral sensitivity of P-gp expressing cells to certain chemical drugs might be utilized to increase the anti-cancer potential of the SLC7A11-targeting agents [100,101]. This evidence concerns the gene SLC7A11 and cancer.